These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 32313004)

  • 1. Genetic characterization of a unique neuroendocrine transdifferentiation prostate circulating tumor cell-derived eXplant model.
    Faugeroux V; Pailler E; Oulhen M; Deas O; Brulle-Soumare L; Hervieu C; Marty V; Alexandrova K; Andree KC; Stoecklein NH; Tramalloni D; Cairo S; NgoCamus M; Nicotra C; Terstappen LWMM; Manaresi N; Lapierre V; Fizazi K; Scoazec JY; Loriot Y; Judde JG; Farace F
    Nat Commun; 2020 Apr; 11(1):1884. PubMed ID: 32313004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer.
    Brennen WN; Zhu Y; Coleman IM; Dalrymple SL; Antony L; Patel RA; Hanratty B; Chikarmane R; Meeker AK; Zheng SL; Hooper JE; Luo J; De Marzo AM; Corey E; Xu J; Yegnasubramanian S; Haffner MC; Nelson PS; Nelson WG; Isaacs WB; Isaacs JT
    JCI Insight; 2021 Apr; 6(8):. PubMed ID: 33724955
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Blee AM; He Y; Yang Y; Ye Z; Yan Y; Pan Y; Ma T; Dugdale J; Kuehn E; Kohli M; Jimenez R; Chen Y; Xu W; Wang L; Huang H
    Clin Cancer Res; 2018 Sep; 24(18):4551-4565. PubMed ID: 29844131
    [No Abstract]   [Full Text] [Related]  

  • 4. Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer.
    Zou M; Toivanen R; Mitrofanova A; Floch N; Hayati S; Sun Y; Le Magnen C; Chester D; Mostaghel EA; Califano A; Rubin MA; Shen MM; Abate-Shen C
    Cancer Discov; 2017 Jul; 7(7):736-749. PubMed ID: 28411207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance.
    Miyamoto DT; Zheng Y; Wittner BS; Lee RJ; Zhu H; Broderick KT; Desai R; Fox DB; Brannigan BW; Trautwein J; Arora KS; Desai N; Dahl DM; Sequist LV; Smith MR; Kapur R; Wu CL; Shioda T; Ramaswamy S; Ting DT; Toner M; Maheswaran S; Haber DA
    Science; 2015 Sep; 349(6254):1351-6. PubMed ID: 26383955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer.
    Singh N; Ramnarine VR; Song JH; Pandey R; Padi SKR; Nouri M; Olive V; Kobelev M; Okumura K; McCarthy D; Hanna MM; Mukherjee P; Sun B; Lee BR; Parker JB; Chakravarti D; Warfel NA; Zhou M; Bearss JJ; Gibb EA; Alshalalfa M; Karnes RJ; Small EJ; Aggarwal R; Feng F; Wang Y; Buttyan R; Zoubeidi A; Rubin M; Gleave M; Slack FJ; Davicioni E; Beltran H; Collins C; Kraft AS
    Nat Commun; 2021 Dec; 12(1):7349. PubMed ID: 34934057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significance.
    Kaur H; Samarska I; Lu J; Faisal F; Maughan BL; Murali S; Asrani K; Alshalalfa M; Antonarakis ES; Epstein JI; Joshu CE; Schaeffer EM; Mosquera JM; Lotan TL
    Prostate; 2020 Sep; 80(12):1012-1023. PubMed ID: 32649013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TMPRSS2:ERG blocks neuroendocrine and luminal cell differentiation to maintain prostate cancer proliferation.
    Mounir Z; Lin F; Lin VG; Korn JM; Yu Y; Valdez R; Aina OH; Buchwalter G; Jaffe AB; Korpal M; Zhu P; Brown M; Cardiff RD; Rocnik JL; Yang Y; Pagliarini R
    Oncogene; 2015 Jul; 34(29):3815-25. PubMed ID: 25263440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.
    Attard G; Swennenhuis JF; Olmos D; Reid AH; Vickers E; A'Hern R; Levink R; Coumans F; Moreira J; Riisnaes R; Oommen NB; Hawche G; Jameson C; Thompson E; Sipkema R; Carden CP; Parker C; Dearnaley D; Kaye SB; Cooper CS; Molina A; Cox ME; Terstappen LW; de Bono JS
    Cancer Res; 2009 Apr; 69(7):2912-8. PubMed ID: 19339269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross modulation between the androgen receptor axis and protocadherin-PC in mediating neuroendocrine transdifferentiation and therapeutic resistance of prostate cancer.
    Terry S; Maillé P; Baaddi H; Kheuang L; Soyeux P; Nicolaiew N; Ceraline J; Firlej V; Beltran H; Allory Y; de la Taille A; Vacherot F
    Neoplasia; 2013 Jul; 15(7):761-72. PubMed ID: 23814488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroendocrine Differentiation in Prostate Cancer: Emerging Biology, Models, and Therapies.
    Puca L; Vlachostergios PJ; Beltran H
    Cold Spring Harb Perspect Med; 2019 Feb; 9(2):. PubMed ID: 29844220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer.
    Sperger JM; Emamekhoo H; McKay RR; Stahlfeld CN; Singh A; Chen XE; Kwak L; Gilsdorf CS; Wolfe SK; Wei XX; Silver R; Zhang Z; Morris MJ; Bubley G; Feng FY; Scher HI; Rathkopf D; Dehm SM; Choueiri TK; Halabi S; Armstrong AJ; Wyatt AW; Taplin ME; Zhao SG; Lang JM
    J Clin Oncol; 2021 Sep; 39(26):2926-2937. PubMed ID: 34197212
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Bhagirath D; Yang TL; Tabatabai ZL; Majid S; Dahiya R; Tanaka Y; Saini S
    Clin Cancer Res; 2019 Nov; 25(21):6532-6545. PubMed ID: 31371344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer.
    Yasumizu Y; Rajabi H; Jin C; Hata T; Pitroda S; Long MD; Hagiwara M; Li W; Hu Q; Liu S; Yamashita N; Fushimi A; Kui L; Samur M; Yamamoto M; Zhang Y; Zhang N; Hong D; Maeda T; Kosaka T; Wong KK; Oya M; Kufe D
    Nat Commun; 2020 Jan; 11(1):338. PubMed ID: 31953400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The identification of a TNBC liver metastasis gene signature by sequential CTC-xenograft modeling.
    Vishnoi M; Liu NH; Yin W; Boral D; Scamardo A; Hong D; Marchetti D
    Mol Oncol; 2019 Sep; 13(9):1913-1926. PubMed ID: 31216110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer.
    Puca L; Gavyert K; Sailer V; Conteduca V; Dardenne E; Sigouros M; Isse K; Kearney M; Vosoughi A; Fernandez L; Pan H; Motanagh S; Hess J; Donoghue AJ; Sboner A; Wang Y; Dittamore R; Rickman D; Nanus DM; Tagawa ST; Elemento O; Mosquera JM; Saunders L; Beltran H
    Sci Transl Med; 2019 Mar; 11(484):. PubMed ID: 30894499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide.
    Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Zhu Y; Silberstein JL; Taylor MN; Maughan BL; Denmeade SR; Pienta KJ; Paller CJ; Carducci MA; Eisenberger MA; Luo J
    J Clin Oncol; 2017 Jul; 35(19):2149-2156. PubMed ID: 28384066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isolation and characterization of castration-resistant prostate cancer LNCaP95 clones.
    Leung JK; Tam T; Wang J; Sadar MD
    Hum Cell; 2021 Jan; 34(1):211-218. PubMed ID: 32954481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of Total, PTEN
    Di Lorenzo G; Zappavigna S; Crocetto F; Giuliano M; Ribera D; Morra R; Scafuri L; Verde A; Bruzzese D; Iaccarino S; Costabile F; Onofrio L; Viggiani M; Palmieri A; De Placido P; Marretta AL; Pietroluongo E; Luce A; Abate M; Navaeiseddighi Z; Caputo VF; Celentano G; Longo N; Ferro M; Morelli F; Facchini G; Caraglia M; De Placido S; Buonerba C
    Clin Genitourin Cancer; 2021 Oct; 19(5):e286-e298. PubMed ID: 33958297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of phospholipase Cε knockdown with GANT61 sensitizes castration‑resistant prostate cancer cells to enzalutamide by suppressing the androgen receptor signaling pathway.
    Sun W; Li L; Du Z; Quan Z; Yuan M; Cheng H; Gao Y; Luo C; Wu X
    Oncol Rep; 2019 May; 41(5):2689-2702. PubMed ID: 30864728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.